本文選題：心力衰竭 + 治療��； 參考：《北京協(xié)和醫(yī)學院》2017年碩士論文

【摘要】：目的:我國心力衰竭(心衰)住院患者的治療和預后情況以往有所報道,但門診心衰患者的情況尚不了解,本研究旨在了解真實世界中我國心衰患者的臨床特征,治療情況及預后。方法:采用前瞻性、多中心注冊研究,連續(xù)入選2012年12月至2014年11月在我國不同地區(qū)、不同級別的24家醫(yī)院門診或住院的972例心衰患者,收集患者的人口學和臨床資料以及治療情況。在1年時進行隨訪,采用配對卡方分析比較患者的藥物治療情況。觀察的終點事件為全因死亡、因心衰再住院以及全因死亡/因心衰再住院的聯(lián)合終點,分別應用單變量和多變量Cox和logistic回歸模型分析評價終點事件的影響因素。結果:患者平均年齡65.6±13.0歲,男性557例(57.3%),門診患者610例(62.8%)。合并高血壓、糖尿病、心肌梗死或行血運重建術、卒中史的患者分別占59.1%、21.7%、25.2%和16.9%,紐約心臟病協(xié)會(NYHA)Ⅲ/Ⅳ級者占58%,其中住院患者明顯高于門診患者(70.4%vs 50.8%,P0.001)。無論住院或門診就診以及左室射血分數(shù)(LVEF)50%或≥50%,走坡路時呼吸困難的心衰患者均占90%以上,而走平路時呼吸困難、夜間陣發(fā)性呼吸困難和休息時呼吸困難在住院的心衰患者(72.1%vs 56.9%,49.3%vs 31.3%,29.6%vs 15.1%,均 P0.001)和 LVEF50%的患者(67.5%vs 56.6,P0.005,;43.3%vs 35.1%,P0.05;27.9%vs 15.0%,P0.001)更多。入選時心電圖顯示房顫或房撲者227例(25.7%),53.4%的患者超聲心動圖LVEF50%。缺血性心臟病是心衰的首要病因(52.2%),其次是高血壓性心臟病(16.9%)、擴張型心肌病(14.1%)和瓣膜性心臟病(9.5%)。入選時心衰的藥物治療中血管緊張素阻滯劑(ABs)(血管緊張素轉換酶抑制劑(ACEI)或血管緊張素受體阻滯劑(ARB))的使用率為65.7%(ACEI 34.3%,ARB 32.0%),其次為阿司匹林、利尿劑和β-受體阻滯劑,分別為62.6%、60.5%和60.0%。超過一半的患者使用了醛固酮受體拮抗劑,硝酸酯類藥和地高辛的使用分別為36.2%和26.1%。門診患者中β-受體阻滯劑的應用多于住院患者(63.1%vs 54.7%,P0.05),LVEF50%的患者β 受體阻滯劑(66.5%vs 60.5%,P0.05)、ACEI(45.4%vs 29.7%,P0.001)和醛固酮受體拮抗劑(70.5%vs 47.0%,P0.001)的使用均明顯多于LVEF≥500%的患者。隨著入選時NYHA心功能級別增加,ACEI和醛固酮受體拮抗劑的使用逐漸增多。入選時β-受體阻滯劑、ACEI、ARB劑量達標率分別為5.2%、29.9%、10.6%,其中門診患者β-受體阻滯劑(6.5%vs 2.5%,P0.05)、ACEI(34.0%vs 25.1%)的劑量達標率高于住院患者(P0.05)。與入選時相比,一年隨訪時除抗凝劑的應用率有所增加外(11.6%vs9.9%,P0.05),β-受體阻滯劑和ACEI使用率無變化,而ARB(30.2%vs32.7%,P0.05)和醛固酮受體拮抗劑(47.5%vs 53.6%,P0.001)的使用率有所減少。ARB使用率降低主要見于門診患者,而醛固酮受體拮抗劑使用率降低主要見于住院患者。一年隨訪時僅ACEI的劑量達標率高于入選時(36.6%vs29.9%,P0.05)。一年隨訪時,NHYAⅢ/Ⅳ級的患者比例明顯低于入選時(29.1%vs 56.5%,P0.001),患者的全因死亡率為7.9%,因心衰再住院率和聯(lián)合終點發(fā)生率分別為30.2%,和33.9%,其中住院患者因心衰再住院率(37.2%vs 26.00%,P0.001)以及聯(lián)合終點發(fā)生率(42.0%vs 29.1%,P0.001)均明顯高于門診患者。多因素Cox回歸分析顯示糖尿病、吸煙,雙側胸腔積液和硝酸酯類藥物應用是心衰患者一年全因死亡的獨立危險因素;多因素Logistic回歸分析顯示一年隨訪時因心衰再住院和聯(lián)合終點的獨立危險因素均為NYHA心功能Ⅲ/Ⅳ級、糖尿病,X線心/胸比0.5和慢性阻塞性肺疾病(COPD)。結論:首先,缺血性心臟病是我國心衰患者的主要病因,擴張型心肌病導致的心衰已明顯超過風濕性心臟瓣膜病。其次,心衰患者的規(guī)范化藥物治療有待于提高,不僅體現(xiàn)在有改善預后意義的抗心衰藥物使用率低,依從性差,更體現(xiàn)在β-受體阻滯劑、ACEI和ARB的劑量達標率低。第三,無論從心衰患者的癥狀,NYHA心功能分級,藥物治療和預后方面,住院和門診的心衰患者均存在差異,因此,未來應更加重視對全部心衰患者的評估,更全面地了解我國心衰患者的真實情況。
[Abstract]:Objective: the treatment and prognosis of patients with heart failure (heart failure) in our country have been reported in the past, but the situation of patients with heart failure is not yet understood. The purpose of this study is to understand the clinical characteristics, treatment and prognosis of heart failure patients in the real world. Methods: a forward-looking, multi center registration study and continuous selection from December 2012 to 2014. The demographic and clinical data and treatment of 972 patients with heart failure in 24 hospitals of different levels and in 24 hospitals of different levels were collected and compared with the patient's drug treatment at 1 years. The end point of the observation was all cause death, heart failure hospitalization and all causes. The combined endpoints of death / heart failure and rehospitalization were analyzed with univariate and multivariate Cox and logistic regression models respectively. Results: the average age of the patients was 65.6 + 13 years, 557 men (57.3%), 610 outpatients (62.8%). Combined with high blood pressure, diabetes, myocardial infarction, or revascularization, stroke history The patients accounted for 59.1%, 21.7%, 25.2% and 16.9% respectively, and the New York Heart Association (NYHA) class III / IV was 58%, and the hospitalized patients were significantly higher than the outpatients (70.4%vs 50.8%, P0.001). No matter the hospitalization or outpatient clinic and the left ventricular ejection fraction (LVEF) 50% or more 50%, the patients with dyspnea were more than 90% in the walk road, while the breathing was on the flat road. Difficulties, nocturnal paroxysmal dyspnea, and breathing difficulties during rest in hospitalized heart failure patients (72.1%vs 56.9%, 49.3%vs 31.3%, 29.6%vs 15.1%, P0.001) and LVEF50% patients (67.5%vs 56.6, P0.005, 43.3%vs 35.1%, P0.05; 27.9%vs 15%, P0.001). 227 cases (25.7%), 53.4% of patients with atrial fibrillation or atrial flutter (25.7%) were selected at the time of entry. Acoustic cardiogram LVEF50%. ischemic heart disease is the primary cause of heart failure (52.2%), followed by hypertensive heart disease (16.9%), dilated cardiomyopathy (14.1%) and valvular heart disease (9.5%). Angiotensin blocker (ABs) (angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (AR) in the drug treatment of heart failure at the time of selection (AR) B)) use of 65.7% (ACEI 34.3%, ARB 32%), followed by aspirin, diuretics and beta blockers, 62.6%, 60.5%, and more than half of the patients with aldosterone receptor antagonists, nitrate and digoxin used in 36.2% and 26.1%. outpatients for beta blockers more than hospitalized patients. Patients (63.1%vs 54.7%, P0.05), LVEF50% patients with beta blockers (66.5%vs 60.5%, P0.05), ACEI (45.4%vs 29.7%, P0.001) and aldosterone receptor antagonists (70.5%vs 47%, P0.001) were significantly more used in patients with LVEF than 500%. With the increase in the grade of NYHA cardiac power, the use of the antagonists and aldosterone receptor antagonists increased gradually. The dose rate of beta blocker, ACEI, and ARB was 5.2%, 29.9%, 10.6%, respectively. The rate of beta blocker (6.5%vs 2.5%, P0.05), ACEI (34.0%vs 25.1%) was higher than that of hospitalized patients (P0.05). The rate of anticoagulant application was increased (11.6%vs9.9%, P0.05) and beta receptor resistance at one year follow-up. The use of hysteresis and ACEI was not changed, while the use of ARB (30.2%vs32.7%, P0.05) and aldosterone receptor antagonists (47.5%vs 53.6%, P0.001) decreased the.ARB use rate and decreased mainly in outpatients, while the reduction of aldosterone receptor antagonists was mainly in hospitalized patients. The rate of only ACEI at one year follow-up was higher than that of the admission (3 6.6%vs29.9%, P0.05). At a one-year follow-up, the proportion of patients with NHYA III / IV was significantly lower than that of the admission (29.1%vs 56.5%, P0.001). The total cause mortality was 7.9%, the rate of rehospitalization and the joint endpoint of heart failure were 30.2%, and 33.9% respectively, and the rate of hospitalization for heart failure (37.2%vs 26%, P0.001) and the incidence of joint endpoints were in the hospital. 42.0%vs 29.1%, P0.001) were significantly higher than outpatients. Multifactor Cox regression analysis showed that diabetes, smoking, bilateral pleural effusion, and nitroester use were independent risk factors for one year all cause death in patients with heart failure; multiple factor Logistic regression analysis showed an independent risk of heart failure rehospitalization and joint endpoint at one year's follow-up. NYHA cardiac function was grade III / IV, diabetes, X-ray cardiac / thoracic ratio 0.5 and chronic obstructive pulmonary disease (COPD). Conclusion: first, ischemic heart disease is the main cause of heart failure in China. Dilated cardiomyopathy is obviously more than rheumatic valvular heart failure. The drug use rate is low, the compliance is poor, and the dose rate of ACEI and ARB is low. Third, there are differences in the symptoms of heart failure, the classification of NYHA heart function, the drug treatment and the prognosis in both hospitalized and outpatient heart failure patients, therefore, the future should be more aggravated. All patients with heart failure can be assessed for a more comprehensive understanding of the real situation of patients with heart failure in China.
【學位授予單位】：北京協(xié)和醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R541.6

【相似文獻】

相關期刊論文 前10條

1 鄒華;何泉;;MicroRNAs與心力衰竭的診斷和治療[J];檢驗醫(yī)學與臨床;2014年10期

2 馬湘俊;β-受體阻滯劑在擴張型心肌病心力衰竭治療中的應用[J];心腦血管病防治;2001年03期

3 劉廣才;β-受體阻滯劑治療慢性充血性心力衰竭40例療效觀察[J];中國基層醫(yī)藥;2002年01期

4 盧文娟,于祥志;β-受體阻滯劑治療慢性充血性心力衰竭療效觀察[J];農(nóng)墾醫(yī)學;1999年06期

5 陳曼華;β-受體阻滯劑治療慢性充血性心力衰竭的研究進展[J];心臟雜志;2002年05期

6 葛長江;小劑量β-受體阻滯劑治療慢性充血性心力衰竭48例臨床分析[J];現(xiàn)代醫(yī)藥衛(wèi)生;2002年05期

7 何輝輝,陳友佳;β-受體阻滯劑在不同疾病的正確應用[J];中國臨床醫(yī)生;2002年06期

8 沙慶勇;;β-受體阻滯劑在心血管病中的應用[J];新疆醫(yī)學;2002年03期

9 李國英;β-受體阻滯劑在慢性充血性心力衰竭中的療效分析[J];山西醫(yī)藥雜志;2004年02期

10 張秀芳,董榮;β-受體阻滯劑治療慢性充血性心力衰竭40例療效觀察[J];醫(yī)學綜述;2005年05期

相關會議論文 前3條

1 張影清;;β-受體阻滯劑應用于慢性阻塞性肺疾病合并冠心病患者的臨床觀察[A];華東地區(qū)第13屆中青年呼吸論壇論文集[C];2012年

2 楊天倫;方晗;;冠心病患者靜息心率達標情況及β-受體阻滯劑使用情況的現(xiàn)況調查[A];中華醫(yī)學會第十五次全國心血管病學大會論文匯編[C];2013年

3 張影清;;β-受體阻滯劑應用于慢性阻塞性肺疾病合并冠心病患者的臨床觀察[A];2012年浙江省內科學年會論文集[C];2012年

相關重要報紙文章 前2條

1 陶春祥;β-受體阻滯劑治療心血管疾病近況[N];中國醫(yī)藥報;2004年

2 毛杉杉;特定運動項目禁用β—受體阻滯劑[N];中國醫(yī)藥報;2008年

相關博士學位論文 前1條

1 王吉元;心衰1號方治療高血壓病、糖尿病、冠心病并發(fā)慢性心衰的臨床研究[D];中國中醫(yī)科學院;2017年

相關碩士學位論文 前10條

1 劉少帥;心力衰竭972例患者臨床特征、治療現(xiàn)狀及預后分析[D];北京協(xié)和醫(yī)學院;2017年

2 邢阿光;不同病因所致心功能Ⅳ級心力衰竭患者血清腦鈉肽水平觀察[D];承德醫(yī)學院;2017年

3 趙漢君;MicroRNA-499在新發(fā)心力衰竭患者治療前后表達水平變化的研究[D];寧夏醫(yī)科大學;2017年

4 蘇振;經(jīng)胸震波治療缺血性心力衰竭的機制研究[D];昆明醫(yī)科大學;2017年

5 王平;左西孟旦注射液治療心肌梗死后心力衰竭的療效觀察[D];青島大學;2017年

6 張新雨;住院射血分數(shù)中間范圍的心力衰竭患者的臨床特點和預后分析[D];鄭州大學;2017年

7 徐繼堯;亞硝酰氫對心力衰竭大鼠心臟功能及肌漿網(wǎng)鈣泵的影響[D];山西醫(yī)科大學;2017年

8 高小群;腎功能損傷對N末端B型利鈉肽原應用于心力衰竭診斷的影響[D];青島大學;2017年

9 武硯;血清VitD水平與老年充血性心力衰竭的相關性研究[D];青島大學;2017年

10 成軍霞;貧血、鐵缺乏與心衰[D];北京協(xié)和醫(yī)學院;2017年

，

本文編號：2076648